EMA Authorised: Cotellic (cobimetinib hemifumarate) — Roche Registration GmbH

View source ↗

Summary

EMA authorised Cotellic (cobimetinib hemifumarate) for melanoma; the marketing authorisation holder is Roche Registration GmbH with a decision dated 24 June 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cotellic (cobimetinib)

Snippet

Status: Authorised. Therapeutic area: Melanoma. MAH: Roche Registration GmbH. Decision date: 24/06/2025